<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37204819</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2059-7983</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>Pt 6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Acta crystallographica. Section D, Structural biology</Title><ISOAbbreviation>Acta Crystallogr D Struct Biol</ISOAbbreviation></Journal><ArticleTitle>Structure-based discovery of an antipsychotic drug, paliperidone, as a modulator of human superoxide dismutase 1: a potential therapeutic target in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>544</EndPage><MedlinePgn>531-544</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1107/S2059798323003649</ELocationID><Abstract><AbstractText>Aggregates of the antioxidant superoxide dismutase 1 (SOD1) are one of the major contributors to the pathogenesis of amyotrophic lateral sclerosis (ALS). Mutations in SOD1 lead to an unstable structure and aggregation that perturbs the balance of reactive oxygen species in cells. Oxidation damage to the solvent-exposed Trp32 also causes aggregation of SOD1. Here, the FDA-approved antipsychotic drug paliperidone is identified to interact with Trp32 of SOD1 by structure-based pharmacophore mapping and crystallographic studies. Paliperidone is used for the treatment of schizophrenia. The crystal structure of the complex with SOD1, refined to 2.1&#x2005;&#xc5; resolution, revealed that the ligand binds to the SOD1 &#x3b2;-barrel in the &#x3b2;-strand 2 and 3 regions, which are known to scaffold SOD1 fibrillation. The drug also makes substantial &#x3c0;-&#x3c0; interaction with Trp32. Microscale thermophoresis studies confirm significant binding affinity of the compound, suggesting that the ligand can inhibit or prevent tryptophan oxidation. Thus, the antipsychotic drug paliperidone or a derivative may avert SOD1 aggregation and can be used as a lead for ALS drug development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aouti</LastName><ForeName>Snehal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biophysics, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka 560029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padavattan</LastName><ForeName>Sivaraman</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1732-5421</Identifier><AffiliationInfo><Affiliation>Department of Biophysics, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka 560029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Balasundaram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biophysics, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka 560029, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ICMR/001/101/2015/00787</GrantID><Agency>Indian Council of Medical Research</Agency><Country/></Grant><Grant><GrantID>SR/FST/LS-I/2017(C)</GrantID><Agency>Department of Science and Technology, Ministry of Science and Technology, India</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Crystallogr D Struct Biol</MedlineTA><NlmUniqueID>101676043</NlmUniqueID><ISSNLinking>2059-7983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8P8USM8FR</RegistryNumber><NameOfSubstance UI="D000068882">Paliperidone Palmitate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068882" MajorTopicYN="N">Paliperidone Palmitate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">antipsychotic drugs</Keyword><Keyword MajorTopicYN="N">binding assays</Keyword><Keyword MajorTopicYN="N">crystal structure</Keyword><Keyword MajorTopicYN="N">modulators</Keyword><Keyword MajorTopicYN="N">paliperidone</Keyword><Keyword MajorTopicYN="N">pharmacophore mapping</Keyword><Keyword MajorTopicYN="N">superoxide dismutase</Keyword><Keyword MajorTopicYN="N">tryptophan oxidation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37204819</ArticleId><ArticleId IdType="doi">10.1107/S2059798323003649</ArticleId><ArticleId IdType="pii">S2059798323003649</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>